Chugai Pharmaceutical Co Ltd announced that the results of the Japanese phase III study (J-ALEX) of Alecensa®, in ALK fusion...
Read moreAstraZeneca announced that benralizumab, a potential new medicine and anti-eosinophil monoclonal antibody, was well tolerated and achieved the primary endpoint...
Read moreMallinckrodt plc a leading global specialty biopharmaceutical company, today confirmed enrollment of the first patient in the company's Phase 4...
Read moreAstraZeneca announced that benralizumab, a potential new medicine and anti-eosinophil monoclonal antibody, was well tolerated and achieved the primary endpoint...
Read moreAllergan plc announced that two pivotal trials of the Oculeve Intranasal Tear Neurostimulator, OCUN-009 and OCUN-010, each met their primary...
Read more
Otsuka Holdings Co Ltd announced the signing of a development and commercialization agreement with ReCor Medical Inc. (“ReCor”), together with...
Read moreEisai Co Ltd announced that its U.S. subsidiary Eisai Inc. has received approval from the U.S. FDA for an additional...
Read moreChugai Pharmaceutical announced that "Actemra® Subcutaneous Injection" , the humanized antihuman IL-6 receptor monoclonal antibody, successfully met the primary endpoint...
Read morePfizer Inc announced results of two Phase 3 studies demonstrating the immunogenicity of TRUMENBA® (Meningococcal Group B Vaccine) against...
Read moreSun Pharma announced that one of its wholly owned subsidiaries has received approval from USFDA for its New Drug Application...
Read more
Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.
